Who makes EB-1020 SR2?

EB-1020 SR2 is developed by Neurovance, Inc..

Last reviewed 2026-04-19 · How we verify

EB-1020 SR2

Neurovance, Inc. · Phase 1 active Small molecule

At a glance

Generic name	EB-1020 SR2
Sponsor	Neurovance, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EB-1020 SR2 CI brief — competitive landscape report
EB-1020 SR2 updates RSS · CI watch RSS
Neurovance, Inc. portfolio CI